B85/100
Desk Score
Dispatch #14Editorial
REMEVi
Straightforward mid-market injectable pricing, verified, across all 50 states.
Visit REMEVi ↗Editorial — no commercial relationship.
- Semaglutide
- $199/mo
- Tirzepatide
- $269/mo
- Coverage
- All 50 states
- Brand-name
- Compounded only
Desk Score breakdown
Each of the six scored dimensions. See the methodology.
Price transparency84/100
State access96/100
Molecule range82/100
Onboarding speed82/100
Support responsiveness82/100
Licensing & trust88/100
What the Desk likes
- LegitScript-verified operator
- Nationwide 50-state coverage
- Clear mid-market pricing on both molecules
Where points come off
- Injectable only — no oral route
- No brand-name access
The Desk's briefing — B
Best for: Patients who want a plain, verified injectable program with nationwide reach.
REMEVi ranks #14 of 25 providers scored — see #1, CoreAge Rx on the board.
Related dispatches
- #1CoreAge Rx94/100 · A
- #2Vaylen91/100 · A−
- #3Ondra Health90/100 · A−
- #4Invigor Medical90/100 · A−
- #5Vytora Health90/100 · A−
- #6Tyde Wellness89/100 · B+
- #7Effecty89/100 · B+
- #8Curex88/100 · B+
- #9AgelessRx87/100 · B+
- #10BetterMe Rx86/100 · B
- #11Eden85/100 · B
- #12Fitish85/100 · B
- #13RxSpan MD85/100 · B
- #15ShedRx83/100 · B
- #16Ro81/100 · B−
- #17Primary Clinic (Direct GLP)80/100 · B−
- #18Peak Wellness80/100 · B−
- #19Found79/100 · C+
- #20Mochi Health79/100 · C+
- #21Optimized Health78/100 · C+
- #22Fella Health78/100 · C+
- #23Henry Meds77/100 · C+
- #24Hims & Hers76/100 · C
- #25HydraMed76/100 · C
Pricing and verification reflect REMEVi's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on REMEVi's site. Not medical advice; see our disclosure.